title: Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice.
abstract: Thrombopoietin (TPO), the ligand for the c-mpl receptor, has been shown to be the major regulator of platelet production. Mice deficient in either c-mpl or TPO generated by homologous recombination show a dramatic decrease in platelet counts, but other blood cell counts are normal. Because TPO treatment of myelosuppressed mice not only enhances the recovery of platelets but also accelerates erythroid recovery, we investigated the levels of myeloid and erythroid progenitor cells in TPO-or c-mpl-deficient mice. Our results show that the number of megakaryocyte, granulocyte-macrophage, erythroid, and multilineage progenitors are significantly reduced in the bone marrow, spleen, and peripheral blood of either TPO-or c-mpl-deficient mice. Administration of recombinant murine TPO to TPO-deficient mice and control littermate mice significantly increased the absolute number of myeloid, erythroid, and mixed progenitors in bone marrow and spleen. This increase was especially apparent in TPO-deficient mice where numbers were increased to a level greater than in diluent-treated control mice and approached or equaled that in the TPO-treated control mice. Moreover, TPO-administration greatly increased the number of circulating progenitors as well as platelets in both TPO-deficient and control mice. Furthermore, the megakaryocytopoietic activity of other cytokines in the absence of a functional TPO or c-mpl gene was shown both in vitro and in vivo.
authors.affiliation: Department of Molecular Oncology, Genentech, Inc, South San Francisco, CA 94080, USA.
authors.forename: K
authors.initials: K
authors.lastname: Carver-Moore
authors.forename: H E
authors.initials: HE
authors.lastname: Broxmeyer
authors.forename: S M
authors.initials: SM
authors.lastname: Luoh
authors.forename: S
authors.initials: S
authors.lastname: Cooper
authors.forename: J
authors.initials: J
authors.lastname: Peng
authors.forename: S A
authors.initials: SA
authors.lastname: Burstein
authors.forename: M W
authors.initials: MW
authors.lastname: Moore
authors.forename: F J
authors.initials: FJ
authors.lastname: de Sauvage
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D019070:Cell Lineage; D002478:Cells, Cultured; D016207:Cytokines / Q000494:pharmacology; D015672:Erythroid Precursor Cells / Q000187:drug effects; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D007958:Leukocyte Count; D008533:Megakaryocytes / Q000473:pathology; D051379:Mice; D018345:Mice, Knockout; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins / Q000172:deficiency* / Q000235:genetics / Q000502:physiology; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; D013154:Spleen / Q000473:pathology; D013926:Thrombopoietin / Q000172:deficiency* / Q000235:genetics / Q000502:physiology
chemical_list: D016207:Cytokines; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human; D013926:Thrombopoietin